Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

Tisotumab vedotin is an investigational antibody–drug conjugate (ADC) for treatment of solid tumors expressing tissue factor with accelerated approval from the US Food and Drug Administration for treatment of recurrent or metastatic cervical cancer with disease progression during or after chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibiansky, Leonid, Passey, Chaitali, Voellinger, Jenna, Gunawan, Rudy, Hanley, William D., Gupta, Manish, Winter, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574719/
https://www.ncbi.nlm.nih.gov/pubmed/35932175
http://dx.doi.org/10.1002/psp4.12850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574719/
https://www.ncbi.nlm.nih.gov/pubmed/35932175
http://dx.doi.org/10.1002/psp4.12850

Ejemplares similares